Streetbeat News

Products Services

IBM

Financial giants have made significant bullish moves on IBM options, with 18 unusual trades detected. The majority of these trades are puts, with a focus on a price band between $195.0 and $240.0. Analysts have mixed ratings on IBM, with a consensus target price of $206.5.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 6:31 pm

GOOG

GOOGL

NVDA

Perplexity AI's revenue and usage have surged by 700% since the start of the year, driven by a $250 million funding round. The company is transitioning from a subscription-based model to an advertising model to compete with Google. Investors include Nvidia, Jeff Bezos, and others. The company has faced plagiarism allegations but has made changes to address them.

Portfolio Pulse from Michael Juliano

August 09, 2024 | 6:18 pm

PBR

Petrobras CEO announced a slight market share loss in fuel sales recently and stated that raising prices would lead to further decline. The repurchase of the RLAM refinery from Mubadala's Acelen is not a priority.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 6:10 pm

BYDDF

BYDDY

Toyota Motor Corp (NYSE:TM) has seen a significant decline in its stock price, now trading at $168, which is 33% below its 52-week high. The downturn is attributed to a broader sell-off in Japanese equities and unwinding of speculative yen carry trades. Despite no immediate rate hikes from the Bank of Japan, Toyota faces challenges including reliance on hybrid technology and certification irregularities. Technical indicators show a bearish trend, with the stock below key moving averages.

Portfolio Pulse from Surbhi Jain

August 09, 2024 | 6:07 pm

ELF

e.l.f. Beauty, Inc. (NYSE:ELF) reported strong first-quarter results and raised its fiscal year outlook, expecting a 25%-27% year-over-year increase in net sales. Analysts provided mixed ratings, with price forecasts ranging from $161 to $260. The company is expanding internationally, entering new markets like Australia and Germany.

Portfolio Pulse from Nabaparna Bhattacharya

August 09, 2024 | 5:56 pm

GILD

Gilead Sciences, Inc. (NASDAQ:GILD) reported strong Q2 results with revenue and EPS beating expectations. Despite improved investor sentiment, analysts warn of limited growth at current stock levels due to high revenue baselines and competitive pressures. The company raised its fiscal year 2024 adjusted EPS forecast and reaffirmed its product sales outlook. Analysts maintain neutral ratings with slight price target increases.

Portfolio Pulse from Vandana Singh

August 09, 2024 | 5:48 pm

CBOE

CBOE has withdrawn and resubmitted its application to list options on spot Bitcoin ETFs, signaling potential engagement from the SEC. Analysts view this as a positive sign, although further approvals are needed. Optimism remains for Bitcoin ETF options to be available by Q4 2023.

Portfolio Pulse from Murtuza Merchant

August 09, 2024 | 5:44 pm

DAT

FIVN

Five9, Inc. (NASDAQ:FIVN) shares are trading lower due to a revenue guidance cut for 2024, despite beating Q2 revenue and EPS estimates. Analysts have lowered price targets but maintain positive ratings, citing potential profitability and AI benefits. ProShares Big Data Refiners ETF (NYSE:DAT) offers exposure to FIVN.

Portfolio Pulse from Lekha Gupta

August 09, 2024 | 5:39 pm

AAP

AMZN

BKNG

CAVA

HLT

NKE

RCL

TSLA

The article highlights significant options activity in the Consumer Discretionary sector, focusing on trades involving companies like TSLA, NKE, RCL, SG, GM, AMZN, AAP, CAVA, HLT, and BKNG. These activities include both bullish and bearish sentiments, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 5:35 pm

SNY

SPRY

The FDA has approved ARS Pharmaceuticals Inc's (NASDAQ: SPRY) Neffy nasal spray for emergency allergy treatment, providing an alternative to EpiPen and other autoinjectors like Sanofi SA's (NASDAQ: SNY) Auvi-Q. This approval comes ahead of the PDUFA target action date and is based on studies showing comparable efficacy to existing epinephrine injection products.

Portfolio Pulse from Vandana Singh

August 09, 2024 | 5:34 pm